SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Sanofi India Ltd

BSE: 500674 NSE: SANOFI ISIN: INE058A01010
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Sanofi India Ltd belong to?
Sanofi India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Sanofi India Ltd a good quality company?
Sanofi India Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Sanofi India Ltd undervalued or overvalued?
Sanofi India Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Sanofi India Ltd a good buy now?
Sanofi India Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Sanofi India Ltd?
Sanofi India Ltd revenue growth is -8.7% for FY-2025 , which is in line with its 5 year CAGR of -8.7% , indicating stable growth.
Q.2 Gross Profit margin of Sanofi India Ltd?
Sanofi India Ltd Gross profit margin which is the profit after deduction of direct costs, is 24.5% for FY-2025 , which is below its 5 year median of 26.4% , indicating decreasing margins.
Q.3 Operating Profit Margin of Sanofi India Ltd?
Sanofi India Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 26.74% for FY-2025 , which is above its 5 year median of 25.38% indicating increasing margins.
Q.4 Net Profit Margin of Sanofi India Ltd?
Sanofi India Ltd Net Profit Margin is 17.78% for FY-2025 , is below with its 5 year median of 18.27%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 24.5 26.4
Operating Profit Margin 26.74 25.38
Net Profit Margin 17.78 18.27
Q.5 Return on Asset of Sanofi India Ltd?
Sanofi India Ltd Return on Asset is 7.18%, which is below its 5 year historical median of 7.65%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Sanofi India Ltd?
Sanofi India Ltd Return on equity is 44.5% for FY-2025 , which is above its historical median of 36.73%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Sanofi India Ltd?
Sanofi India Ltd Return on capital employed is 55.46% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Sanofi India Ltd?
Sanofi India Ltd Cash conversion cycle is 9 days, above its historical median of 9 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.46 0.47
ROE 44.5 36.73
ROCE 55.46 49.47
Cash Conversion Cycle 9 days 9 days
Q.9 Debt to Equity ratio of Sanofi India Ltd?
Sanofi India Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Sanofi India Ltd?
Sanofi India Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Sanofi India Ltd?
Promoters hold 60.40% of the Sanofi India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Sanofi India Ltd vs industry peers?
Sanofi India Ltd revenue CAGR is -8.74% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,837.4 137.1
Gross Profit 450.1 15.1
Operating Profit 491 16
Net Profit 327 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.46 0.8
ROE 44.5 8.91
ROCE 55.46 11.59
Cash Conversion Cycle (days) 8.62 76

Valuation & price assessment

Q.1 Stock return of Sanofi India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -1.9% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -1.9% -15.1% -15.8% -42.9%
Q.3 Valuation ratios of Sanofi India Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 25.1 0.00 40.28
Price to Book 12.1 7.49 2.77
Price to Sales 4.46 6.43 2.65
EV to EBITDA 15.51 0.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×